Competitive position
Search documents
Amentum Stock Draws Fresh Buying Amid $14.4 Billion Revenue Year and 51% Stock Run
Yahoo Finance· 2025-12-24 18:47
Amentum Holdings, Inc. is a leading provider of specialized technical and operational services, serving defense, intelligence, and commercial markets at scale. The company leverages advanced technology and domain expertise to deliver solutions in critical infrastructure, cyber intelligence, and mission support. Its diversified contract base and focus on high-value, complex projects underpin its competitive position in the government services sector.As of Wednesday, AMTM shares were priced at $29.86, up a st ...
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Driven Brands and Jasper Therapeutics on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Globenewswire· 2025-11-23 04:49
Core Insights - Bragar Eagel & Squire, P.C. is investigating officers and directors of Driven Brands Holdings, Inc. and Jasper Therapeutics, Inc. on behalf of long-term stockholders due to class action complaints filed against both companies [1][4] Driven Brands Holdings, Inc. (NASDAQ: DRVN) - A class action complaint was filed against Driven Brands on December 22, 2023, alleging that the company made materially false and misleading statements regarding its ability to integrate acquired businesses and the performance of its car wash segment [2][3] - The complaint claims that Driven Brands misrepresented its integration capabilities as a "core strength" and assured investors of "significant progress" in integrating its U.S. auto glass businesses, while downplaying issues related to customer demand in its car wash segment [3] Jasper Therapeutics, Inc. (NASDAQ: JSPR) - A class action complaint was filed against Jasper Therapeutics on September 19, 2025, alleging that the company made materially false and misleading statements about its business operations and compliance policies [4][5] - The complaint highlights that Jasper lacked necessary controls to ensure third-party manufacturers complied with cGMP regulations, which increased risks for ongoing studies and overstated the company's financial and clinical prospects [5]